OTCPK:TCLI.F

Stock Analysis Report

Executive Summary

Theraclion SA develops, manufactures, and markets Echopulse ultrasound medical imaging tool for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners.

Snowflake

Fundamentals

Limited growth with weak fundamentals.

Share Price & News

How has Theraclion's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

TCLI.F

3.2%

US Medical Equipment

3.4%

US Market


1 Year Return

n/a

TCLI.F

10.0%

US Medical Equipment

5.4%

US Market

Return vs Industry: Insufficient data to determine how TCLI.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how TCLI.F performed against the US Market.


Shareholder returns

TCLI.FIndustryMarket
7 Day0%3.2%3.4%
30 Dayn/a-1.8%-1.0%
90 Dayn/a-0.4%-0.4%
1 Yearn/a10.9%10.0%7.7%5.4%
3 Yearn/a69.9%64.8%46.2%36.8%
5 Yearn/a128.2%102.9%65.6%47.5%

Price Volatility Vs. Market

How volatile is Theraclion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Theraclion undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Theraclion is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Theraclion has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of TCLI.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Theraclion regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Theraclion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

42.3%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if TCLI.F's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if TCLI.F's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TCLI.F's revenue (42.3% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: TCLI.F's revenue (42.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if TCLI.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Theraclion performed over the past 5 years?

-2.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: TCLI.F is unprofitable, and losses have increased over the past 5 years at a rate of -2.6% per year.

Accelerating Growth: Unable to compare TCLI.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TCLI.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: TCLI.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: TCLI.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: TCLI.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Theraclion's financial position?


Financial Position Analysis

Short Term Liabilities: TCLI.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: TCLI.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: TCLI.F has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: TCLI.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: TCLI.F has a high level of physical assets or inventory.

Debt Coverage by Assets: TCLI.F has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if TCLI.F has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TCLI.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Theraclion's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate TCLI.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TCLI.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if TCLI.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TCLI.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TCLI.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Theraclion's salary, the management and board of directors tenure and is there insider trading?

4.5yrs

Average management tenure


CEO

David Caumartin 0

5.1yrs

Tenure

€293,758

Compensation

Mr. David Caumartin has been the Chief Executive Officer of Theraclion, S.A.S. since September 2014. Mr. Caumartin is healthcare industry specialist with 14 years' experience at GE Healthcare, covering Eur ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether David's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.5yrs

Average Tenure

Experienced Management: TCLI.F's management team is considered experienced (4.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jean-Yves Burel (68yo)

    Chairman & President

    • Tenure: 0yrs
    • Compensation: €10.00k
  • Michel Nuta

    VP of Veins & Chief Medical Officer

    • Tenure: 0yrs
  • David Caumartin

    Chief Executive Officer

    • Tenure: 5.1yrs
    • Compensation: €293.76k
  • Anja Kleber

    VP & Chief Marketing Officer

    • Tenure: 5.1yrs
  • Jose Abellan-Martinez

    Vice President of Sales & Business Development

    • Tenure: 0yrs
  • Roberta Brocardo

    Executive Officer

    • Tenure: 0yrs
  • David Auregan

    Chief Financial Officer

    • Tenure: 3.8yrs
  • Laurence Aucoin

    Vice President of Operations

    • Tenure: 3.3yrs

Board Members

  • Christopher Bödtker

    Director

    • Tenure: 0yrs
  • Renault Saleur

    Director

    • Tenure: 1.7yrs
  • Samuel Levy

    Director

    • Tenure: 3.4yrs
    • Compensation: €11.50k
  • Jean-Yves Burel (68yo)

    Chairman & President

    • Tenure: 0yrs
    • Compensation: €10.00k
  • Ari Kellen (56yo)

    Director

    • Tenure: 0yrs
  • Shawn Langer

    Director

    • Tenure: 0yrs

Company Information

Theraclion SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Theraclion SA
  • Ticker: TCLI.F
  • Exchange: OTCPK
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €13.873m
  • Listing Market Cap: €15.311m
  • Shares outstanding: 14.95m
  • Website: https://www.theraclion.com

Number of Employees


Location

  • Theraclion SA
  • 102, rue Etienne Dolet
  • Malakoff
  • Ile-de-France
  • 92240
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALTHEENXTPA (Euronext Paris)YesOrdinary SharesFREURApr 2014
TCLI.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDApr 2014

Biography

Theraclion SA develops, manufactures, and markets Echopulse ultrasound medical imaging tool for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:48
End of Day Share Price2019/10/01 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.